SPOTLIGHT -
EP. 1: Genetic Alterations in Acute Myeloid Leukemia
EP. 2: Best Practices for NGS Testing in AML
EP. 3: Therapeutic Approaches Based on Mutations in AML
EP. 4: Prognostic Significance of MRD in AML
EP. 5: MRD Assessment and its Clinical Implications in AML
EP. 6: Treatment Strategies and Patient Specific Factors in AML
EP. 7: Consolidation Strategies in AML
EP. 8: Role of Maintenance Therapy in AML
EP. 9: Treatment of AML With Myelodysplasia-Related Changes
EP. 10: Role of Hypomethylating Agents in AML
EP. 11: Management of Adverse Events in Older Patients With AML
EP. 12: Recent Data on the Treatment of Older Patients With AML
EP. 13: Targeting FLT3 in Patients with Relapsed/Refractory AML
EP. 14: Data Supporting Quizartinib in FLT3+ R/R AML
EP. 15: Relapsed vs. Refractory Data for FLT3 Inhibitors in AML
EP. 16: Targeting IDH1/2 in AML
EP. 17: The Future Treatment Landscape of AML
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
